Oxford Biomedica Future Growth

Future criteria checks 1/6

Oxford Biomedica is forecast to grow earnings and revenue by 52.4% and 17.1% per annum respectively. EPS is expected to grow by 54.2% per annum. Return on equity is forecast to be -22.3% in 3 years.

Key information

52.4%

Earnings growth rate

54.2%

EPS growth rate

Biotechs earnings growth	19.4%
Revenue growth rate	17.1%
Future return on equity	-22.3%
Analyst coverage	Good
Last updated	18 Apr 2024

Recent future growth updates

Recent updates

Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?

Oct 19

Oxford Biomedica plc (LON:OXB) Not Doing Enough For Some Investors As Its Shares Slump 28%

Aug 23

Is Oxford Biomedica plc (LON:OXB) Expensive For A Reason? A Look At Its Intrinsic Value

Feb 15

Is Oxford Biomedica (LON:OXB) Using Too Much Debt?

Oct 06

Investors Shouldn't Be Too Comfortable With Oxford Biomedica's (LON:OXB) Robust Earnings

May 02

Investors Who Bought Oxford Biomedica (LON:OXB) Shares Five Years Ago Are Now Up 202%

Dec 24

The Independent Non-Executive Director of Oxford Biomedica plc (LON:OXB), Andrew John Heath, Just Sold 79% Of Their Holding

Dec 02

Oxford Biomedica (LON:OXB) Is In A Good Position To Deliver On Growth Plans

Dec 01

Earnings and Revenue Growth Forecasts

LSE:OXB - Analysts future estimates and past financials data (GBP Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	208	-1	12	32	3
12/31/2025	161	-18	-10	3	7
12/31/2024	130	-39	-33	-27	6
12/31/2023	90	-89	-50	-30	7
6/30/2023	119	-62	-9	6	N/A
3/31/2023	130	-50	-19	-3	N/A
12/31/2022	140	-39	-29	-13	N/A
9/30/2022	133	-32	-31	-17	N/A
6/30/2022	126	-25	-33	-21	N/A
3/31/2022	134	-3	-9	2	N/A
12/31/2021	143	19	16	25	N/A
9/30/2021	139	19	15	26	N/A
6/30/2021	135	19	15	26	N/A
3/31/2021	111	6	2	15	N/A
12/31/2020	88	-6	-10	3	N/A
9/30/2020	77	-9	-16	-1	N/A
6/30/2020	66	-13	-22	-6	N/A
3/31/2020	65	-14	-26	-5	N/A
12/31/2019	64	-16	-29	-4	N/A
9/30/2019	64	-12	-26	-4	N/A
6/30/2019	64	-8	-23	-4	N/A
3/31/2019	65	0	-10	4	N/A
12/31/2018	67	8	3	13	N/A
9/30/2018	62	4	9	18	N/A
6/30/2018	57	0	16	23	N/A
3/31/2018	47	-5	8	13	N/A
12/31/2017	38	-9	1	3	N/A
9/30/2017	34	-10	-3	-1	N/A
6/30/2017	31	-11	-7	-6	N/A
3/31/2017	29	-14	N/A	-4	N/A
12/31/2016	28	-17	N/A	-2	N/A
9/30/2016	26	-16	N/A	-1	N/A
6/30/2016	24	-16	N/A	-1	N/A
3/31/2016	20	-15	N/A	-7	N/A
12/31/2015	16	-13	N/A	-13	N/A
9/30/2015	15	-12	N/A	-12	N/A
6/30/2015	13	-10	N/A	-10	N/A
3/31/2015	13	-9	N/A	-8	N/A
12/31/2014	14	-9	N/A	-6	N/A
9/30/2014	11	-9	N/A	-8	N/A
6/30/2014	8	-10	N/A	-9	N/A
3/31/2014	7	-11	N/A	-10	N/A
12/31/2013	5	-11	N/A	-11	N/A
9/30/2013	5	-10	N/A	-10	N/A
6/30/2013	5	-10	N/A	-9	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OXB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OXB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OXB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OXB's revenue (17.1% per year) is forecast to grow faster than the UK market (3.3% per year).

High Growth Revenue: OXB's revenue (17.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: OXB is forecast to be unprofitable in 3 years.

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Oxford Biomedica Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 12%

Price target decreased by 9.5% to UK£6.79

Consensus revenue estimates fall by 27%

Oxford Biomedica plc Provides Revenue Guidance for the Year 2023 and 2024

Price target decreased by 11% to UK£8.21

Price target decreased by 8.2% to UK£10.00

Recent updates

Oxford Biomedica plc Announces Board Changes

Oxford Biomedica plc to Report Fiscal Year 2023 Results on Apr 29, 2024

New minor risk - Shareholder dilution

Oxford Biomedica plc (LSE:OXB) completed the acquisition of additional 3.2% stake in ABL EUROPE S.A.S. from TSGH.

Oxford Biomedica plc Provides Business Update

Consensus EPS estimates fall by 12%

Oxford Biomedica plc (LSE:OXB) entered into a sale and purchase agreement to acquire ABL EUROPE S.A.S. from TSGH for €15 million.

Price target decreased by 9.5% to UK£6.79

New minor risk - Share price stability

Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?

Consensus revenue estimates fall by 27%

Non-Executive Chair recently bought UK£99k worth of stock

Oxford Biomedica Talks to Buy ABL Europe

Oxford Biomedica Talks to Buy ABL Europe

First half 2023 earnings: EPS and revenues miss analyst expectations

Oxford Biomedica plc Provides Revenue Guidance for the Year 2023 and 2024

Price target decreased by 11% to UK£8.21

Oxford Biomedica plc (LON:OXB) Not Doing Enough For Some Investors As Its Shares Slump 28%

Oxford Biomedica plc to Report First Half, 2023 Results on Sep 20, 2023

Price target decreased by 8.2% to UK£10.00

Oxford Biomedica plc Launches TetraVectaTM - the Next Generation Lendediviral Vector System

Oxford Biomedica plc, Annual General Meeting, Jun 23, 2023

Oxford Biomedica plc, Annual General Meeting, Jun 23, 2023

Price target increased by 40% to UK£11.83

Price target decreased by 25% to UK£8.43

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 25% to UK£8.43

High number of new directors

Is Oxford Biomedica plc (LON:OXB) Expensive For A Reason? A Look At Its Intrinsic Value

Oxford Biomedica plc Announces Siyamak Rasty Will Not Be Standing for Re-Election

Consensus forecasts updated

Oxford Biomedica Appoints Frank Mathias as Board Director

High number of new directors

Kadans Science Partner B.V. agreed to acquire Windrush Court facility from Oxford Biomedica plc (LSE:OXB) for £60 million.

Price target decreased to UK£11.19

Consensus forecasts updated

Is Oxford Biomedica (LON:OXB) Using Too Much Debt?

Consensus forecasts updated

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Oxford Biomedica plc Provides Earnings Guidance for the Second Half of 2022

Oxford Biomedica plc to Report First Half, 2022 Results on Sep 15, 2022

Oxford Biomedica plc(LSE:OXB) dropped from FTSE 350 Index (GBP)

Investor sentiment deteriorated over the past week

Oxford Biomedica Notes Announcement That FDA Has Lifted Clinical Hold on Homology Medicines' Phenix Trial

John Dawson Has Steps Down from the Oxford Biomedica Plc's Board of Directors

Consensus forecasts updated

Price target decreased to UK£14.99

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investors Shouldn't Be Too Comfortable With Oxford Biomedica's (LON:OXB) Robust Earnings

High number of new directors

Interim CEO & Chairman recently bought UK£343k worth of stock

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 136%

Oxford Biomedica plc Provides Revenue Guidance for the Year 2022

Oxford Biomedica plc Announces the Appointment of Namrata P Patel as Independent Non-Executive Director

Oxford Biomedica plc to Report Fiscal Year 2021 Results on Apr 20, 2022

Investor sentiment deteriorated over the past week

Oxford Biomedica plc, Annual General Meeting, Mar 08, 2022

Investor sentiment deteriorated over the past week

Price target increased to UK£18.42

Oxford Biomedica plc announced that it expects to receive £50.000001 million in funding

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.087 loss in 1H 2020)

Price target increased to UK£17.00

Price target increased to UK£14.82

We're Not Worried About Oxford Biomedica's (LON:OXB) Cash Burn

Price target increased to UK£13.52

Non-Executive Director Andrew John Heath has left the company

Chief Technical Officer exercised options and sold UK£598k worth of stock

Full year 2020 earnings released: UK£0.078 loss per share (vs UK£0.22 loss in FY 2019)